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ABSTRACT 
The major difficulty in clinical assessment of patients 
with inflanunatory disease, and in the evaluation of 
consequent anti-inflanunatory drug treatment has hitherto 
been the impossibility of quantifying the inflammatory 
process. Clinical methods have proved too rough and 
ready, with unacceptable levels of error even with so-
called objective measurements, while laboratory 
investigation by scintigraphy has been of only limited 
value since it has previously evolved around static 
imaging. 
The introduction of dynamic parametric functional 
imaging, which allows separation of the vascular and 
bony phases of accretion of radioactive material in 
scintigraphy permits the accurate objective 
quantification of the degree of inflanunatory response 
and, as here demonstrated, makes it possible to evaluate 
the modification of that response by anti-inflanunatory 
medication. 
It is also shown also possible to compare clinical and 
objective responses in given patients and (perhaps in 
some respects more importantly) to make objective 
comparisons of the in vivo anti-inflammatory effects of 
a wide range of drugs marketed and prescribed for the 
treatment of the arthritides. 
By this experimental model the anti-inflammatory effects 
of the drugs Indomethacin, Benoxaprofen and Piroxicam 
have been compared in a suitably controlled trial in 
adjuvant induced inflammation in rats. In this study it 
has been shown that neither of the latter two drugs is 
as effective as Indomethacin in the doses quoted, and 
the role of Indomethacin is confirmed as the standard agent 
against which other non-steroidal anti-inflammatory 
medications should be tested in anti-inflammatory drug 
trials. 
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PREFACE 
This study was stimulated by a paper presented at a 
local Medical Society Meeting describing the comparative 
effects of anti-inflammatory drugs on bone damage or 
erosions in the adjuvant arthritic rat. (The adjuvant 
arthritic rat has for some 20 years been one of the 
standard models for evaluation of these types of drugs.) 
Surprisingly, the interpretation in that study was 
entirely subjective and arbitrary. 
It seemed to me that it should be possible objectively 
to quantify this effect. My clinical work with Dr. Murdo 
McLeod and Dr. Alec Houston in the Nuclear Medicine 
Department at the Royal Naval Hospital, Haslar, had 
convinced me of the advantages, particularly the 
objectivity and the reproducibility, of radio-nucleide 
studies in arthritis. 
This study was therefore set up objectively to quantify 
the inflammatory response in the adjuvant arthritic rat. 
I am most grateful to Ms Joanna Hase for her endurance in 
producing the final typescript. 
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1. INTRODUCTION 
Adjuvant arthritis in rats, in which traditionally most 
reliance is placed on the volume changes in the foot as the 
arthritic lesion progresses, has been used for the last 20 
years as a predictive test for anti-inflammatory activity 
in man. 
Killed Mycobacterium tuberculosis in light mineral oil 
(Freund's adjuvant) is injected intradermally into the 
plantar surface of one paw. Over the next 8 to 10 days the 
inflammatory exudate in the foot is readily measurable and 
is known as the A lesion. From day 10 to day 30 a secondary 
wave of inflammation occurs both in the injected paw (called 
the B lesion) and the non-injected hind paw (C lesion). 
This has been shown to be immune mediated (Pearson and Wood 
1959) [211. In fact the arthritis becomes a systemic 
polyarthritis most analgous to Reiter's disease in man with 
some features common to rheumatoid arthritis (Newbould 1963) 
[191. 
Assay against adjuvant induced arthritis has been shown to 
be predictive for clinical activity, for it is known that 
the standard non-steroidal anti-inflammatory drugs 
(Prostaglandin synthetase inhibitors) are active in this 
model, though these compounds are not capable of modifying 
the progressive disease in either animals or man. A 
literature search and discussion with various pharmaceutical 
firms indicated that no published work was available on 
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radio-nucleide functional imaging of adjuvant arthritic 
joints in the early analysis of anti-inflammatory drug 
effect, although there were many studies on the use of 
radio-nucleides in classical rheumatoid arthritic patients 
using static techniques (Collins et al 19711 Berry and 
Huskisson 19741 Deohar et. al. 1973) [8,5,91. 
Evaluation of anti-inflammatory drug effects has progressed 
little in the last two decades. The methods used have 
evolved from the early work of Stoerk and colleagues (1954) 
[271, later progressed by Pearson and his colleages (1956, 
1959) [20,211. These authors show that the intradermal 
injection of an emulsion containing Mycobacterium 
tuberculosis produced a form of reactive arthritis in 10 to 
15 days. This arthritis had many of the features of 
rheumatoid arthritis and thus was a reproduceable model for 
the study of drug effect based on certain measurements such 
as hind foot volume. Subsequent work by Ward and Jones 
(1962) [291 refined the technique as a statistically 
valuable method. 
The method in most common use today involves the intradermal 
injection of 0.05 ml of a fine suspension of dead tubercle 
bacilli in liquid paraffin into the plantar surface of the 
right hind foot of the rat. The development of the 
arthritis follows a persistent pattern. Immediate swelling 
of the injected foot is followed by slow progression for 8 
to 10 days and thereafterwards the development of a remote 
polyarthritis from 10 to 30 days in the non-injected sites, 
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particularly the opposite hind paw knee joint. The arthritis 
has many of the features of both rheumatoid and Reiter's 
reactive arthritis. In these conditions the non-steroida1 
anti-inflammatory drugs are known to have an ameliorating 
effect. Clearly further progression of these techniques is 
desirable, particularly as the interpretation is sUbjective. 
More recently studies have been conducted using X-ray 
analysis to determine the extent of bone damage (erosions) 
in the adjuvant model. As is usual with X-ray analysis, the 
interpretation is difficult and not readily quantifiable. 
Bens1ay and Nickander (1981) [4) showed that anti-
inflammatory drugs had an inhibiting effect on bone damage 
when compared with controls covering a wide range of 
inflammatory compounds. The bone damage was assessed by 
observation of joint space narrowing, periosteal elevation 
and erosions, using an arbitrary scale. 
A percentage inhibition score was produced in comparative 
studies with controls and this was considered to represent 
an advance in assessing the effectiveness of the drug. 
However, reproducibility was uncertain because the visual 
interpretation of the X-ray was subjective and in different 
hands too much inter-observer error would intruge. 
This present investigation was started in 1982 to evaluate 
the use of scintigraphy in animals for the assessment of 
efficiency of anti-inflammatory drugs. There have been 
numerous publications on the use of radio-nuc1eides in the 
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arthritidies, for example by Dick et al (1970, 1976) [11,10], 
and Hoffer and Genant (1976) [14]. Initially the procedure 
was complex and took many hours which negated its true 
value. It was however, even at the earlier stage, useful in 
the detection of synovitis. From the mid-1960s however, 
when Andros and others (1965) [2] introduced Technetium 99m 
into nuclear medicine, it became possible to visualise 
inflammed joints more readily. Technetium offered two main 
advantages, those of a short half life and of lack of high 
energy particles, resulting in low radiation exposure. This 
allows repeated small dosage examinations to be made for 
serial assessments of changes in synovial tissues, and of 
bony change within damaged joints. 
It seems that arthritis is associated with periarticular 
elevation of the periosteum and sub-chondral bone erosions 
followed by increased osteoblastic activity in reaction to 
inflammation. Clearly if both aspects of inflammation, that 
is synovial inflammation (which is represented by increased 
blood flow around the joint) and osteoblastic bony turnover 
can be visualised, a quantitative assessment may then be 
made against controls of the effect of treatment or the 
progression of the disease process. The method used in this 
study was functional or parametric imaging, which measures 
the rate of change of tracer within an organ rather than the 
amount of tracer within the organ at anyone time. 
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2., FUNCTIONAL IMAGING 
Kaihara and his co-workers (1969) [16] were the first to 
offer the new concept of functional imaging in the rapidly 
advancing world of nuclear medicine. They reasoned that if 
one could demonstrate the rate-of-change values for an 
elapsed time period of radionucleide take up in any organ it 
would be more meaningful than a static image gathered over 
the same period. 
By 1973 Weiner and others [30] had, with the improvement in 
isotopes available, (with particular regard to organ 
specificity) advanced the technique, particularly in renal 
studies. They had also recognised its application in other 
organ studies. 
Since that time functional imaging has become one of the 
standard methods of assessment in nuclear medicine. The 
increasing use of the technique by clinicians, confirms the 
role of nuclear medicine as the link between particular 
clinical problems and their solution using organ specific 
radionucleides. 
Whaley and others (1968) [32] worked on methods of 
quantification of joint inflammation showing isotope pickup 
to be a function of severity of joint inflammation, that is 
micro-vascular flow and bony turn-over. They additionally 
suggested that because Technetium was not actively 
concentrated in diseased synovium, the display of isotope 
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(which in their study was a static image) reflected the 
enhanced vascu1arity of the synovial membrane and other 
joint tissues. Dynamic and functional studies have advanced 
to improve the concept. 
Macewan (1979) [17] progressed the argument in his study of 
the knee by predicting in the difficult condition of 
chondromalacia patella that this was a three phase condition 
of increased, normal and absent micro-vascular blood flow. 
This indicated that there was an inflammatory precursor 
stage in osteoarthrosis of short1ived duration. It was 
noted in this study that even the absent blood flow image 
showed as "hot" on dynamic imaging. It was the ability to 
divide the two functions, i.e. microvasculature and bony 
turnover that was significant. 
In dynamic radionuc1eide studies (Houston 1984; Mac1eod 
1984) [15,18] a sequence of images (each of which is a 
frame) is stored in the computer at regular known time 
intervals. Each image is recorded at a previously 
determined elapsed time from the introduction of isotope 
into the body. Dynamic function is expressed as a function 
. of rate of change of these images. 
Functional imaging is the method by.which this dynamic 
sequence may be represented by a single visual display. It 
was designed to compress into this single image a series of 
elapsed time images and has the obvious advantage of 
synthesising large amounts of data and of identifying 
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processes not visualised by inspection of single incidents. 
Regional information or area specific information is often 
obscured by total organ measurement. The main advantage of 
functional imaging is that it will identify focal areas of 
abnormality. This ability to identify areas of damage or 
change is the key to the study in that it can show both 
vascular and bone change in a standard model identifying the 
two elements of the inflammatory process. 
The image or frame is stored as a visual array of picture 
elements or pixe1s. Each contains a.va1ue representing the 
number of counts collected in the study region over a 
specific time scale. There is a sequence of frames in the 
study (usually 20 in number) which is stored in a 64 X 64 
array. Because interpretation through any single dixe1 
(which is defined as the summation into graph form of the 
pixe1s of a specific area in each frame of the study) would 
make quantification difficult due to insufficient 
statistical data, they are summated into a 16 X 16 matrix. 
If one can find some numerical value or parameter for each 
dixe1 an image may be formed to display that parameter 
across the field of view. This is a functional image (or 
parametric image). A simple example will explain the 
concept. If a 3 frame study is taken collected as a 3 X 3 
array, the counts of each pixe1 will be collected (Figure 
2.1). 
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B 
A 
Figure 2.1 
C 
A = Pixel 
. 
. 
I 
A + B + C ete =·Dixel 
Each pixel displays the percentage accretion of the isotope 
at that moment in a region of interest towards the dixel 
(100% accretion) and may De represented as a point on the 
amplitude curve (e.g. Figure 6.1). 
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Each pixel indicates the percentage accretion of the isotope 
at that moment in a region of interest towards the final 
total (100%) accution - the dixel. It may be represented as 
a point on an amplitude curve (see Figure 6.1 (p.37». 
One dixel may peak earlier than another. This may be viewed 
as shades of colour, for example white peaks first, then 
grey, and lastly black (or other colours may be used). The 
aim of the exercise is thus to separate regions of different 
rates of uptake in the image which thus identifies regions 
of different physiological function - which is why 
clinicians also call it functional. 
To apply functional imaging to a particular clinical problem 
successfully, it is first necessary to identify the patho-
physiological functions involved and then ascertain if they 
can be measured using an appropriate mathematical function. 
For example, the uptake of bone scanning radionucleide 
follows the form: 
d(t) = A(l-E Lambda X t). 
This equation contains 2 constants, A and Lambda (used in 
the study of inflammatory arthritis to describe 2 
physiological parameters). These are any given area A equal 
" 
to the number of osteoblasts and Lambda equivalent to the 
microvasculature which brings the substance there. 
The isotope used is 99M Technetium MDP. This particular 
isotope is chosen because it has been shown to be bone 
specific. 
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A1arcon-Segovia and co-workers (1967) (1) demonstrated that 
Technetium had many advantages over other isotopes used.' He 
identified higher uptake in joints affected by the 
inflammatory process than in normal (controlled) or 
degenerated joints. In addition to its advantages of short 
half life, pure gamma emission and minimal radiation 
exposure, its rapid distribution and absence of allergenic 
reaction, which is important in the study model, were also 
emphasised. 
This was shown to be better than iodinated serum albumen, 
Iodine 131 tagged in localisation of inflamed joints (Weiss 
et a1 1965) (31). The early studies used Technetium 
perchenetate, subsequently po1yphosphates were used, 
(Subramanian et al 1972) (28). These showed that these 
polyphosphates offered significant advantages on previously 
used isotopes in respect of bone specificity. Pendergass 
and his colleagues (1973) (22) however found certain 
difficulty in reproducing Weiss's results and considered 
that diphosphonate, which is known to chemiabsorb into 
hydroxyapatite crystals were more stable than polyphosphates 
chemically. 
They considered that methylene diphosphonate would be, if 
suitably labelled, more specific in imaging. From 1973 it 
, 
has been the most widely used isotope allowing good 
reproduceability and producing an excellent marker of 
osteoblastic activity with high accumulation of Technetium. 
Osteoclastic regions show low uptake in tracer studies. 
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It can be deduced therefore that a sound mathematical method 
allied to a good radionucleide will allow this functional 
imaging to proceed in a satisfactory and reproducible 
fashion. Macewen as stated earlier used this technique in 
the study of the pathological knee and was able to show that 
the quantitative hot spot seen in the affected area was due 
to one or other of the parameters of inflammation. 
It was decided in this study therefore that the combination 
of the two techniques allowed the best possible method to 
obtain a quantifiable mathematical end result which could 
be used as a marker in producing a list of drugs in order 
of their effectiveness. 
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3. THE EQUIPMENT 
Nuclear medicine is a 20th century phenomenon. The first 
Nobel prize for Physics was awarded for the work on the 
X-ray (X at that time to signify unknown) by William w~ 
Roentgen. 
Subsequently Rutherford conducted a large series of 
experiments in the identification of radiation emitted by 
various radioactive materials. He was responsible 
eventually for identifying Alpha (helium nuclei), Beta 
(electrons) and Gamma (short wave length electro-magnetic 
radiation) rays. 
Scientific advance with the development of the cyclotron 
made it possible to produce radioactive isotopes and now 
over 1500 isotopes are known of which less than 20 have 
found their way into nuclear medicine. These are 
characterised by a short half life, rapid excretion, 
specificity to an organ and no allergenic interreaction. 
Almost all the diagnostic studies carried out in nuclear 
medicine utilised Gamma rays (electro-magnetic radiation). 
Magnetic radiation is classified by its wavelength and 
Gamma rays come at the far left-hand end of the spectrum, 
between 10-11 and 10-9 Angstrom units. The visible 
spectrum is in the region of 10-5 to 10-3 Angstrom units 
and is shown in the spectrum of radiation (Figure 3.1). 
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Figure 3.1 The e1ectro-magnetic spectrum 
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The isotope used in this experiment is 99M Technetium as 
its Diphosphonate. The superscript M indicates that the 
elemental nucleus is metastable. Such nuclei are said to 
be excited, returning to the ground state by releasing 
energy as Gamma ray emission. (99M Technetium is not 
wholly a Gamma emitter but also produces a very small 
amount of X-ray emission which is not sufficient to 
influence the experimental validity). 
Electro-magnetic radiation, the passage of Gamma rays 
through matter, produces ionisation with scattering, photo-
electric absorption and Compton scattering (defined as the 
"billiard ball" effect of small ions hitting each other). 
The most important is ionisation, ~ith the production of 
free electrons and positive ions. Most detection systems, 
other than scintillation, use this characteristic to detect 
radiation, for example, the Geiger counter. Scintillation 
utilises the phenomenon that certain organic and inorganic 
materials produce visible light for variable periods 
following excitation. Television picture tubes (Cathode-
ray tubes) are the widest known application of this in 
everyday life. In nuclear medicine~ scintigraphy is 
limited to the use of sodium iodide (NaI) to assess photo-
electric absorption. 
Alone, sodium iodide is not a particularly good 
scintillator but its capacity is enhanced tenfold if 0.5% 
thallium iodide is added to it. This is the basis of the 
commercial scintillator. 
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The equipment used in this study was the Siemens ZLC camera 
system which incorporates a large sodium iodide crystal 
giving a wide field of view (Figure 3.2). It has the ability 
to eliminate distortion in imaging, a common feature in 
previous cameras such as the Anger camera. 
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Siemens ZLC camera 
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4. THE DRU GS INVOLVED 
The most commonly used preparations in the management of 
the inflammatory arthritides are termed " the no n-steroidal 
anti-inflammatory drugs " (NSAIDS) . Over t he l ast f ew years , 
a pletho ra o f novel compounds , and many many copies of these 
compounds , all based on the carboxylic acid r adica l, have 
been marketed . Ea c h drug makes significant claims on its 
own behalf for increased efficacy over each or any of its 
rivals . 
The majority of trials on these compounds in clinical 
practice rely on the sUbjective obse rvat ion of patients. 
These observations are published in clinical journals and 
have been shown to be reasonably accurate predictors of 
significance over many years. 
The majorit y of th e papers work on statistical signifi c ance 
and wh en the calculation of probability "P " reaches a value 
of 0 . 05 that l eve l is significant and the drug is declared 
effe c tive . Wha t is un certain , however , is whether the 
patient who is receiving the drug is convi nced himself of 
t he value of 0 . 05! He would probab l y prefer that the 
treatment be considered l ess stat i stically significant and 
more clinically significant. 
The whole purpose of this study is to find an objective a 
priori marker of activity which is reproducible without 
re course to subjective criteria . 
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To illustrate the point, perhaps the most fundamental change 
that has taken place in the understanding of pain to 
illustrate the point as a clinical synd rome is the belated 
recognition that it is not a sensation but more an 
unpleasant emotional experience . This concept of pain was 
first invoked by Benedictus Spinoza (1632-1677) , the Dutch 
philosophe r, who classified it as a localised form of sorrow 
- that is, a primary emot ion. 
Several important clinical consequences arise from this 
obs ervat ion, the main one being that when attempting to 
assess the efficacy of the treatment of pain, one is 
entirely dependent on the patient's report of his own 
in trospective emotional experience . 
It can be seen therefore from this evaluation that it is 
almost impossible to make a coherent statement that pain 
inte nsity mus t bear a direct relationship to the amount of 
tissue disturbance that is provoking it (Williams 1984) 
[ 3 3 ) • 
The drugs us ed are called anti-pyretic analgesics and are 
considered to exert their main clinical effect at a 
peripheral site (Higgs et al 1974) (13). Classically they 
have been shown to modify the nociceptive response induced 
by Bradykinin (nociceptive signifying responding to tissue 
abnormality) . 
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Activation of the kinin-forming syste m is induced by 
injury. The hyperaemia , oedema and pain of an inflammatory 
response can all be mediated by Bradykinin and the peptide 
can be identified in inflammatory exudates in synovi al 
fluids in arthritic joints , that is , per i p heral l y . The non-
steroidal anti-inflammatory drugs are recognised for their 
efficiency in the relief of pain of superficial origin , or 
where there is evidence of tissue damage, e.g. in the 
arthritides and in the non-articular rheumatoid conditions . 
Interest has centred on the role of these drugs in 
inhibiting the enzymatic synthesis of prostaglandins from 
l o ng chain fatty acids . Vane, Smith and Willis with various 
co-workers (e . g. Salmon et all (1978) [25 ] show that the 
anti-pyretic analgesics inhibited this biosynthesis. Over 
the next f ew years it became established that (1) all human 
cells, with th e possible exception of erythrocytes , have 
enzymes for the production of prostaglandins ; (2) that they 
are always released when cellular damage occurs and are 
shown to be inflammatory exudates. Present evidence is they 
are not stored so must be synthesized de novo ; (3) the anti-
pyretic analgesics inhibit the synthe sis of prostaglandins 
but other drugs do not . 
In human studies the subdermal injections of prostaglandins 
El and E2 will produce oedema and lowe r the pain threshold 
but will not produce spontaneous pain. It is the addition 
of bradykinin or histamine which causes the intense pain 
r eaction. The prostaglandins appear, therefore, to be 
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sensitizers of the peripheral nerves to other pain 
mediators . The diagram (Figure 4 . 1) shows the prostaglandin 
cascade and where the various drugs are presumed to act on 
this progression down from the phospholipids in the cell 
membranes to the release of prostaglandins E2 and F2 at the 
end of the arachidonic acid cascade . 
It can be seen from the diagram that the majority of the 
non-steroidal anti -inflammatory drugs exert their effect, 
which is by the direct inhibition of microsomal enzymes, 
cyclo-oxygenase just after the arachidonic acid radical. 
However, total inhibition at this level will cause a degree 
of reflux down through the cyclic ednoperoxide chain into 
the leucotriene pathway . 
Prostaglandin El and E2 Alpha which are the end results of 
the cascade shown promote osteoclastic bone resorption and 
there fore may well be the reason for the osteoporosis and 
erosive changes from the synovial pannus overgrowth at the 
affected joints . Robinson and his co-worker (1975) [24] 
confirmed in vitro experiments that all bone resorption was 
prostaglandin E2 mediated and additionally that it was 
entirely secreted from the rheumatoid synovial tissue in the 
experimental model. It follows that the adequate 
suppression of the E series prostaglandin synthesis by the 
anti-inflammatory anti-pyretic drugs may reduce or prevent 
bone destruction in the rheumatoid arthritides and give a 
reasonable model for treatment. 
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Simple diagram of the Prostaglandin Cascade 
which is the mediator of pain and inflammation 
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Figure 4 . 1 Simple diagram of the Prostaglandin Cascade 
(which is the medi ator of pain a nd inflammat ion) 
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Benslay and Nickander (1981) in their study o n the 
comparative effects of Benoxaprofen on the inhibitory 
action of non-steroidal anti-inflammatory drugs on the 
prostaglandin system , indicated that in high dosage , all 
th e prostaglandin inhibitors were capable of causing bone 
regene ration or osteoblast i c activity and this could be 
conside r ed disease modify ing . 
Th e inhibitory action of these non-steroidal anti-
in flammatory drugs on the prostaglandin system is complex 
and probably only accounts for the short-term effects of 
the drugs used. Other mechanisms may also be involved in 
a chieving longer term benefits . In addition, evidence that 
s ome of these drugs inhibit prostaglandin biosynthes is , 
suggests the possibility of developing drugs capable of 
inh i biting production at t he site of inflamma t ion without 
i nterfering with the gastro-protective function of those 
prostaglandins which act on the gastric mucosa and are 
beneficial , i . e . the prostacyclins. 
The three drugs used were chosen to cover the entire spect rum 
of the non-steroidal anti-inflammatory drugs as discussed . 
The first one was Piroxicam (Figure 4 . 2 ) , whi c h is 
4 Hydroxy-2 Methyl-N (2 Pyridyl) - 2H-l , 2-Benzothiazine, 
1 , l-Dioxide. It is not a true Carboxylic acid as are the 
other two drugs used in th e study . It is an acid by virtue 
of the enolization of the 4 Hydroxy subst i tuent . In 
a ddition t o considerable potency , Piroxicam was considered 
to h ave pharmaco-kinetic properties. 
22 
PIROXICAM 
OH ~-o C-NH \;;
Piroxicam is 4-hydroxy-2-methyl-]\I -(2-pyridyl}-2H-1. 2-benzothiazine 1, 1-dioxide. 
Figure 4.2 The structure of Piroxicam 
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In laboratory animals , there is no spontaneously occurring 
counterpart of the human arthritic process. Therefore, to 
evaluate pote ntial anti - inf l ammatory agents , many animal 
models have been devised , each mimicking one or more of the 
card inal signs of inflammation . Piroxicam i s potent in 
inhibiting adjuvan t induced oedema of the rat foot with a 
potency considered equal to that of Indomethacin and 
greater than that of the majority of others within the 
gener i c g r oup . It i s also an a n ti-pyretic in the rat . It 
was considered ef f ective at 10 mgs . per Kilogram . 
Piroxicam is intrinsica lly a ctive as an anti-inflammatory 
agent and does no t de pend upon adre nal stimulat i o n to 
produce its anti -inflammatory effects . This intrinsic 
a ctivity is most c l ear ly de mo nstrated i n a nti-oedema 
studies in rats in which , both in those adrenalectomised and 
those not , the activity was exactly the same . 
In laboratory animals , Piroxicam has a long plasma half -
life , it i s smoothly absorbed and is eliminated from plasma 
with a half - life of 40-45 hours . Consequent l y it is 
claimed that plasma concentrations are remarkably stable 
between dosing and that single daily doses can lead to 
plateau concentrations maintained for a fu ll 24 hours. By 
v irtue o f its long half-life , plasma concentrations are 
stable at about 3 to 5 micrograms/ml . and it is 
hypothosised that the lack of pharmaco-kinetic in teraction 
between it and other drugs is probably the result of this 
low plasma concentration . In all species, Piroxicam is 
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extensively metabolized with less than 5% being excreted 
unchanged . It is an effective inhibitor of Prostaglandin 
biosynthetase. It seemed therefore that as it was 
comparable in its pharmaco-kinetic c l aims with Indomethacin 
(which has been considered by many to be the bench-mark 
drug by which all others are evaluated) . it i s worthy as 
one of the newer ones . of being included in the study . 
The s e cond drug used was Indomethacin (Rhymer 1979) [231. 
(Figure 4.3) which has been used in the treatment of 
rhe umat i c disorde rs for over 15 years. It has analgesic . 
anti-inflammatory and anti-pyretic actions . It has now 
be come one of the r e feren c e agents used in the field of 
Prostaglandin synthetase inhibition. 
Indomethacin is 1-(p-Chloro benzoil)-5-Methoxy-2-
Methylindole- 3-A cetic Acid. As shown in the diagram. its 
structura l f o rm u la is C19. H16. N04 Cl . 
Indomethacin is well absorbe d after oral administration in 
all animals. and peak plasma levels occur in 0.5 to 2 hours. 
Following oral adm i nistration the absorption of the drug is 
rap id and complete. In ge neral . peak plasma concentrations 
of 2 to 3/ ugrams/ per ml are achieved within 1 to 2 hours but 
conc omitant ingestion of food reduc e s and delays the 
conce ntra t ions without reducing the amount absorbed. 
About 60% of a normal dose is excreted in the urine and 40 % 
is excreted in the faeces after biliary secretion. It is a 
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;r---,- CH zCOOH 
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Cl 
Indomethacin is 1-(p -chlorobenzoyl)-5-methoxy-2-methylindole-3-acetic acid. 
Its empirical formula is CI9 H IS N04 Cl ; molecular weight 357.78. 
Figure 4 . 3 The structure of Indomethacin 
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potent inhibitor of the s yn t hes is of Prostaglandins. I t is 
excreted as a conjugate with glucuroni c a cid. All its 
meta bo lites are devoid of anti- i nflammatory activity (She n 
1965) [ 26] . 
The third drug was Benoxaprofen which i s 2-[ 2-(4-chlorophenyl) 
be n zoxazo l -5 - y l] prop i onic acid (Figure 4.4). It was a new 
non-steroidal anti-inflammatory age nt which was shown to 
share the act i ons of analgesia and antipyresis with some 
evidence of Prostaglandin synthesis inhibition (Cashin et al 
1977) [6] in common wi th other drugs within th e carboxylic 
acid group . Cl a im s were made that becau se its moderate 
inhibition of Prostaglandin synthesis was not consistent 
with its high degree of potency in suppress ing adjuvant -
induced arthritis in rats , it may have had some additio na l 
inhibitory fa ctor . Thi s additional alternat i ve action was 
considered most important if it was t o be used as an anti -
rheumatic agent. The claim was that it suppressed the 
rh eumato i d ar thriti c disease process . 
Thi s particu lar drug ha s subsequently been taken off the 
approved drug list because it wa s considered t o have 
addi tiona l damaging effects on liver and kidne y and was 
respo nsible for some deaths in the elderly . However, at 
the time the study started, . this drug was st i ll in use and 
it wa s f e lt wor thwhile evaluating the claimed effects o n 
bony turnover in respect of erosions and on blood flow in 
r espect of synovial di sease (which were in fac t validated 
using this new technique). In the results section it is 
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Figure 4 . 4 The structure of Benoxaprofen 
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clear that this assessed additional efficacy is in fact not 
borne out , though indeed subsequent to the study and prior 
to the withdrawal of the drug , major doubts were expressed 
as to its novel additional activity as claimed by its 
manufacture rs. This confirms the impression that a formal 
objective test such as functional imaging can in fact refute 
or confirm many of the claims made by drug manufacturers in 
respect of additional properties in their drugs . 
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5. THE EXPERIMENT 
The present studies were designed to identify and compare 
anti-inflammatory effects using scintigraphic evidence of 
both bone damage and synovia l blood flow in the adjuvant 
arthritic rat. 
Beginning on the 15th day of the adjuvant induced disease , 
non-steroidal anti-inflammatory drugs of the 3 groups (I , 
11 and Ill) were administered daily and continued until the 
30th day . This procedure is called the Established 
Adjuvant Arthritic Assay. 
On day 30 , scintigraphic evaluation was carried out using 
the functional imaging technique already described on 
groups of 5 rats, each consisting of one normal control , 
one control rat with untreated adjuvant arthritis and 3 
adjuvant arthritic rats treated respectively wi th 
Indomethacin , Benoxaprofen and Piroxicam (11, III and I). 
Because of c l aims by Bekemeier (1982) [ 3] that seasonal 
variations were noted in hind paw volume in the 
experimental rat with the lowest values obtained in January 
and February and the highest values in June to August , the 
experiment was carried out over a 7 month period from 
January to July to see whether or not in functional imaging 
terms any change could be demonstrated. Bekemeier saw no 
change in the amount of inhibition achieved by 
Phenylbutazone on hind paw oedema but it was considered , 
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for the sake of completeness a nd because thi s was an 
entire l y objective evaluation , that one from each group 
should be assessed in January, March, April, May and June. 
Adjuvant arthritis was induced in adult male rats (Sprague-
Dawley 160-200 grams) by a single subplantar injection of 
Freund's complete adjuvant . 
The suspension (0 . 1 ml) was injected into the subplantar 
region of the hind paw . Hind paw volumes were determined 
by me rcury displacement . On day 14 both hind paws were 
measured and those displaying at least 0 . 5 ml swelling in 
the uninjected paw were selected for the treatment groups . 
The rats were then randomly assigned into groups of four , a 
fifth normal untreated control animal being then added to 
each group . From the next (i.e . the 15th day of the 
adjuvant induced arthritis) non- steroidal anti - inflammatory 
drugs of the groups mentioned (Indomethacin , Benoxaprofen 
and Piroxicam) were administered daily for a further 15 
days (therefore until day 30) so that of the 5 rats in each 
group one was the non-arthritic control, one arthritic rat 
was l eft untreated as the second control and each of the 
other three arthritic ra ts received a different study drug . 
The method of administration is the standard means by which 
all non-steroidal anti-i nflammatory drugs (NSAIDS) are 
given to trial rats. 
The drugs were administered orally suspended in 1% 
Carboxymethyl cellulose. Suspensions were prepared using 
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a tissue mixer model SDT (Te krnar & Co.) . Both adjuvant 
controls and normal non-adjuvant controlled rat s were 
adminis tered the 1% Carboxymethyl cellulose ve hi cle alone . 
Drug doses were as follows:-
Drug I 
Drug 11 
Drug III 
Piroxicam, dosage 10 mgm per kilogram 
Indomethaci n , dosage 2 mgm per kilogram 
Benoxaprofen , dosage 5 mgm per kilogram 
This procedure is called the Established Adjuvant Arthri t ic 
Assay . 
On the 30th day scintigraphic evaluation was carried out 
using functional imaging o n the groups of five. Each 
animal wa s anae sthetised using 15 mgms of veterinary 
Nembuta l administered by intra-peritoneal i njection . 
A f emoral venous catheter was the n inse rted a nd secu r ed . 
15 milli curies of 99M Technetium MDP was injected v ia th e 
catheter and washed through with 1 ml of normal saline (to 
prevent accumulation at the injection site , a problem 
encountered by Dick and his co-workers (1970)) . In this 
study no signif ican t accumulation was noted except in rat 4 
where blood flush was seen to interfere slightly with the 
amplitude of the curve but not the shape or fit". Counting 
was started immediately after the injection was washed 
throu gh and continued for exactly 20 minutes . 
At 20 minutes the accumulated data was assessed as follows . 
32 
Each colour change through these 3 phases is standardised 
to a factor of 10. 
Each picture display is howeve r standardised to its own 
maximum uptake, in whichever dixel is hottest, and cannot 
be compared wi t h ano t her giving a purely qualitative 
evaluation of the dixel counts (which can be seen in 
Appe ndix A) for each joint studied. It was felt that to 
show individual p i ctures of each joint would be 
unnecessarily repetit ive so a standard for all groups was 
chose n. 
In group 2 , which comprised the ad j uvant arthritic 
u ntreated group of animals , the amplitudes show more 
variation related to the t ime of yea r, as shown by 
Bekeme i er (197 8) [ 3 ] worst in January and February and at 
their l east in the Summer months . However, the rate 
constant as the asses sed blood flow (microvasculature) is 
r emarkably constant. In comparative human studies examples 
of whi c h are shown later , an inflamrned knee will have an 
increased amplitude and the rate cons ta n t will approach 
2 . 0 . 
In group 3 , the Indomethacin t reated group , all t he results 
equate towards normal with a mean rate constant (Lambda of 
54 ) • 
In the qualitative evaluation it is shown that both the 
amplitude and rate constant values are reduced but 
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comparison in visual terms cannot be made without reference 
to figures shown in the Appendix. They are in fact 
virtually indistinguishable from the normal . It is known 
that Indomethacin can cause aseptic necrosis (or ischae mic 
dama ge) to bone following long - term ingestion in the huma n . 
No evidence of this was demonstrated in the short-term 
animal studies at the dosage pe r kilog r am (10 mg) used. In 
group 3 , tha t i s the Benoxaprofen treated group , amplitud e 
values show s ignif icant reduction towards the norma l l eve l , 
the asymptote fo r the hips be ing 44, th e normal controls 
averaged 28 .0 , the rate constant value is also reduced to 
0.6 which equates to normal levels (0.5) and shows this drug 
to be an effective ant i-inflammatory approximately equal in 
value to Piroxicam which is studied in group 4 and shown to 
ha ve an a mpl i tude of 41 and a rate constant value not 
dissimilar to that of the other two treated groups . They do 
not equate , however , in absolute values to the Indomethacin 
g roup which was the most effective . 
Indomethacin has become, in anti-inflammatory Drug Trials, 
one of t he standards against which all of the others are 
tested. In this study i t can be seen that neither of the 
other study groups is quite as efficient in reducing the 
blood flow which has been shown to be an accurate marker of 
synovial activity, whi ch is the most significant change in 
the arthritic mode l . 
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6 . RESULTS 
The normal untreated group determines the standards for the 
major parameters to be studied , that is, bony turnover and 
mi crovasculature , displayed as amplitude and rate constant 
(Lambda) . 
The joint numbers 1-4 in each study are in order , the left 
hip , the right hip , the left knee and the right knee . It 
can b e seen that the amplitude values in all 7 controls are 
of the same order of magnitude (Table 6 . 1) (Appendix) . The 
red line on each graph is a computerised "best fit" to the 
plotted curves (white) (Figure 6 . 1) and can be shown to be 
very accurate , thus reducing the route mean square 
deviation , which is a form of mobile standard deviation 
along the whole line of the asymptote . It i s known that the 
dynamic curve for bone, using 99 M Technetium is close to 
i ts asympote (ma ximal amplitude) at 20 minute s . This is of 
particular value because the study period in each of the 
mode ls is exactly 20 minutes. In the simple compartmental 
mode l proved by Charkes (19 80) [7 ], the value of Lambda in 
bo ne should be constant . Howeve r , a c ertain amount of 
variation may take place as a function of compartmental 
overlap af ter a certain period . A diagram of the 
compartmental mode l is shown and discussed in Chapter 2 . 
As a result , the normal ampl i tude and rate constant 
(Lambda) pattern must be established for a given skeletal 
regi o n in each study model. Subsequent deviations from 
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NORMAL CONTROL 
RAT JOINT AMPLITUDE RATE RMS 
CONSTANT DEVIATION 
1 1 48. 15 .519 1. 683 
1 2 25 . 72 .601 1.069 
1 3 6.81 .615 .623 
1 4 15. 56 .4 88 . 574 
13 1 39 . 97 .801 .739 
13 2 28 . 96 . 501 1. 678 
13 3 5 . 69 . 45 8 .434 
1 3 4 5 . 17 . 526 .37 8 
20 1 40 . 65 . 551 1. 04 9 
20 2 44.74 . 527 1. 436 
20 3 7.85 .4 5 1 5 . 283 
20 4 7.91 .5 08 . 314 
27 1 25 .2 2 .607 6.46 9 
27 2 24.23 .87 3 .861 
27 3 1. 38 . 322 2 . 471 
27 4 1. 95 .6 52 . 174 
28 1 29 . 07 .691 .57 5 
28 2 27 .4 5 .67 0 . 663 
28 3 4.17 .4 16 2 . 69 3 
28 4 2 . 66 . 435 . 183 
29 1 38 . 47 . 641 5 . 202 
29 2 28 . 65 .529 .856 
29 3 4. 28 . 556 8. 388 
29 4 4 . 06 .358 .28 9 
30 1 55 . 13 .60 6 2.333 
30 2 39 . 14 .584 1. 034 
30 3 6 .7 9 . 377 1. 407 
30 4 6 . 01 . 349 . 420 
Table 6 . 1 Ampl i t ude , a cc r et i o n rate and standard 
devia t i on ( RMS) for normal control rats. 
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Figure 6.1 shows amp litude curves in n orma l (untreated) 
contro l rat : t he hips on the top line and the knees o n the 
lowe r line graphs. 
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this establ ished normal l eve l can then be identified and 
r e lated to specific lesions. 
In th is study normal control amplitude values for the rat ' s 
hips are shown in Figure s 6 . 1 (upper line) a nd the left and 
right knee s (bottom line) . Figure 6 . 2 shows an adjuvant 
control with the same joint distribution and d e mo nstrates a n 
increase of greater than a factor of 5 . These curves are 
highly comparable and standardised. 
The rate constant values showed r emarkable consistency 
indicating that microvasculature in this mode l produces a 
constant rate of flow in all joints, the volume changes 
purely r e la ting to the size of the joint . The average mean 
rat e constant is approximate ly 0 . 5 which is accepted as the 
normal for this rat study . 
In human studies the accepted normal rate constant (bearing 
in mind Charkes ' statement t hat it has to be evaluated for 
each study group) i s 1 . 0. The r oot mean square deviation 
(RMS) which is best described as a mobile standard 
deviation shows remarkabl y little variance in any of the 
normal contro l animals. 
Their qualitative display in this s er i es of r e sults of t he 
normal , shown in Figure 6 . 3 has a colour display of 
amplitude in the l e ft-hand p i cture and a colour display of 
rate constant in the right of each group. The colour 
scaling is from white as the maximum pick up in each study 
down to blue through red, yellow and green. 
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Figure 6 . 2 shows an untre a ted adjuvant control with the hips 
o n the upper line and th e knees on the lower line graph 
showing an increase of gre ater than a f actor of 5 . 
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Figure 6 . 3 A a functional imag e of a normal (upper) an d 
un t r e ate d adjuvant (lower) rat. 
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A whole body image of the animal (Figure 6 . 4) allowed the 4 
joints being studied (i . e. the left knee , right knee , left 
hip and right hip) to be isolated as regions of interest 
(ROI) in the computer . Table 6 . 11 shows the square area of 
these regions of interest in pixel size . The advantages of 
using circumscribed regions of interest is that only the 
joints involved are analysed. Background radiation and 
specific organ involvement (such as the excreting kidney and 
rapidly filling bladder) are eliminated . Failure to 
eliminate this extraneous radiation would have the effect of 
r educing the signal recorded. Four animals did not have 
their regions of interest specifically isolated because of 
technical faults on the ZLC 70 gamma camera . They were 
counted instead on the PHO gamma IV camera which has no zoom 
facility. However, even in this slightly modified study , 
the uptake curves were identical in shape and they were 
considered valid within the experiment . 
So consistent are the findings in each of the 5 models 
(normal control , adjuvant arthritic control and drug 
treated groups I , 11 and III (Figures 6.1 , 6 . 5 , 6 . 12)) that 
one example of each suffices to demonstrate the typical 
values of all (Tables 6 . 111 - 6 . VI) . They include the 
amplitude of uptake (asymptote) , the rate constant (Lambda) , 
the root mean square deviation (which is a mobile standard 
deviation along the whole curve of amplitude) and finally a 
fun ctional image as a photographic image. 
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50 
4 0 
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47 
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38 
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53 
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28 
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30 
60 
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73 
41 
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69 
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chosen 
Table 6 . Il Square areas of regions of interest by pixel 
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size 
Figure 6 . 4 shows a whole body image in an adjuvant 
(untreated) model, from which regions of interest (ROI) can 
be selected. (The bright areas indicate the hips and knees 
in the animal - the central and brightest zone is the 
rapidl y filling bladder.) 
43 
Figure 6 . 5 An Indomethacin whole body image from which 
r egions of interest were chosen for the study . 
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Figure 6 . 6 Ind ome thacin treated amplitude curves 
showing a tend e ncy towards normal (see Figure 6 . 1) . 
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Figure 6 . 7 Comparative functional images of Benoxaprofen 
against Indomethacin showing amplitude on the left-hand 
image s and rate constant on the right-hand images . 
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Figure 6 . 8 Be noxa profen treated whole body image from 
which regions of interest were chosen for the study. 
(The bright c e ntral region is the biadder . ) 
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Figure 6.9 Benoxaprofen treated amplitude curve s for 
knee s and hips (upper and lower graph images) which t e nd 
t owards normal (see Figure 6 . 1) 
(Note: t he amplitude has been r educed from a mean of 156 
(adjuvant control) to 38. 7/ 49 . 8 in the hips ( L&R) and leans 
towards normal . ) 
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Figure 6.10 Piroxicam whole body image from which regions 
of interest (ROI) were chosen . 
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Figure 6.11 Functional image of Piroxicam trea~ed rat 
showing amplitude in the left-hand image and rate constant 
in the right. 
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Figure 6.12 is Piroxicam amplitude (asymptotic) curves which 
can be compared directly with the normal curves in Figure 
6 . 1 and are seen to tend towards normal. 
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ADJUVANT CONTROL 
RAT JOINT AMPLITUDE RATE CONSTANT RMS 
2 1 53.89 . 886 1. 352 
2 2 15 . 87 .676 1. 639 
2 3 4.84 .310 . 244 
2 4 6 . 37 . 346 . 326 
6 1 16 . 44 1. 992 .456 
6 2 32 . 03 .405 . 796 
6 3 6.57 . 730 3 . 482 
6 4 31. 33 . 353 . 392 
10 1 55.86 . 321 13 . 797 
10 2 57 . 07 .444 2.000 
10 3 9 . 78 . 434 1. 673 
10 4 14.40 .611 .462 
16 1 65 . 16 .4 49 3.387 
16 2 45.69 .430 1. 890 
16 3 36 . 55 . 381 3 . 440 
16 4 46.49 . 529 1. 410 
17 1 151.43 .731 3.922 
17 2 94.43 .555 2 . 263 
17 3 101. 86 . 504 13 . 372 
17 4 128.96 . 530 1. 922 
22 1 47.49 .429 1. 083 
22 2 57 . 56 .580 1. 646 
22 3 37 . 93 . 281 2 . 593 
22 4 80.88 .364 2.619 
Table 6 . 111 Amplitude, accretion rate and standard 
deviation (RMS) for untreated adjuvant control rats . 
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ERROR 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
INDOMETHACIN 
RAT JOINT AMPLITUDE RATE CONSTANT RMS ERROR 
4 1 29 . 02 . 425 1. 44 0 0 
4 2 25.47 6.688 21.154 0 
4 3 6 . 38 .549 . 291 0 
4 4 10 . 97 . 416 1.277 0 
11 1 28 . 84 .599 2.827 0 
11 2 16.58 . 324 . 880 0 
11 3 7.03 . 416 30.929 0 
11 4 5 . 12 .533 .502 0 
15 1 17 . 74 . 456 1.172 0 
15 2 37 . 03 .474 2 . 557 0 
15 3 2.70 . 394 .276 0 
15 4 6.85 . 931 . 445 0 
19 1 27 . 11 . 280 1. 442 0 
19 2 24.48 . 911 1.161 0 
19 3 9.37 . 490 .502 0 
19 4 13.68 . 521 3.949 0 
24 1 53 . 69 . 412 1. 910 
24 2 53.44 .818 3.869 
24 3 8 . 70 . 472 . 542 
24 4 18 . 25 . 738 7 . 838 
Table 6.IV Amplitude, accretion rate and standard deviation 
(RMS) for Indomethacin treated rats. 
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BENOXAPROFEN 
RAT JOINT AMPLITUDE RATE CONSTANT RMS ERROR 
3 1 38 . 45 .859 1 . 238 0 
3 2 27 . 99 . 800 .933 0 
3 3 6.01 . 419 . 378 0 
3 4 9 . 13 .831 . 307 0 
7 1 21. 03 .641 1. 839 0 
7 2 7 . 46 .989 . 295 0 
7 3 3 . 87 .4 49 2.481 0 
7 4 7 . 58 . 993 . 374 0 
9 1 28.68 . 465 1. 460 0 
9 2 17 . 76 . 400 1. 420 0 
9 3 2 .78 .472 . 191 0 
9 4 6 . 94 . 605 . 422 0 
14 1 42 . 59 . 519 1. 855 0 
14 2 40 . 01 . 5ll 1. 967 0 
14 3 6 . 45 .460 4 . 609 0 
14 4 10 . 91 . 830 . 514 0 
18 1 37.55 . 7 94 . 990 0 
18 2 40.07 .653 2 . 243 0 
18 3 6 . 71 . 378 3 . 903 0 
1 8 4 14.75 .605 . 377 0 
23 1 53 . 83 .4 64 1. 560 0 
23 2 41.53 . 520 1. 569 0 
23 3 5 . 89 . 425 3.ll3 0 
23 4 6.45 . 517 . 275 0 
Table 6 . V Amplitude , accretion rate , and standard deviation 
(RMS) in Benoxaprofen treated rats . 
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PIROXICAM 
RAT JOINT AMPLITUDE RATE CONSTANT RMS ERROR 
5 1 40 . 99 . 720 1. 782 0 
5 2 38.26 .752 1. 659 0 
5 3 9.53 . 461 .391 0 
5 4 1. 47 1. 992 . 456 0 
8 1 23 . 47 . 549 .559 0 
8 2 26 . 28 . 632 1.132 0 
8 3 3 . 53 .462 . 769 0 
8 4 6 . 89 .878 .449 0 
12 1 26 . 72 . 577 .779 0 
12 2 40 . 86 1. 094 . 706 0 
12 3 5.24 . 471 1.265 0 
12 4 5.79 .932 . 342 0 
21 1 36 . 74 . 363 1. 482 0 
21 2 42.30 . 832 3.320 0 
21 3 3 .5 3 . 329 . 177 0 
21 4 5.17 . 376 .241 0 
25 1 47. 34 . 583 3.871 
25 2 37 . 91 .736 . 790 
25 3 5.15 . 405 . 730 
25 4 9 . 79 . 744 .282 
26 1 32.77 . 986 . 896 0 
26 2 50.85 .528 2.027 0 
26 3 3 .7 5 . 175 . 107 0 
26 4 11. 68 .263 . 393 0 
Table 6 . VI Amplitude , accretion rate and standard deviation 
(RMS) in Piroxicam treated rats . 
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7. DISCUSSION 
Joint scintigraphy was introduced in the 1960s by Weiss 
[ 31] and by Alarcon-Sergovia [ 1 ], who showed t hat the 
uptake of Technetium 99m per technetate was increased in 
inflamed joints as compared to no rmal ones . 
The localisation of these isotopes in inflamed joints 
r esu lts from increased synovia l vascularity associated with 
synovitis . Synovitis is the hallmark of inflammatory 
arthritis and the producer of prostaglandins at local and 
peripheral joint sites which are the mediators of pain and 
inflamma tion . Th e main isotope us ed nowadays is 99m 
Technetium M. D. P., a bone seeking nu cleide . 
In synovitis, two phases of increased uptake are 
recognised , an early vascular phase, wi th in minutes , and a 
delayed phase at about 20 minutes when it is known that in 
dynamic studies the uptake curve for bone is close to its 
asymptote , equat ing to the maximal amplitude . 
Abnormal static scintigraphy with 99m Technetium M.D . P . 
correlates well with clinically apparent synovitis and may 
eve n exceed t h e accuracy of the Physician in diagnosing 
c lini ca lly detectable synovitis. At times therefore, joint 
scans can predict si tes where clinically apparent synovitis 
later develops. Any inflamed joint may produce a positive 
scintiscan . 
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Studies of rheumatoid arthritis , and, in the animal model, 
adjuvant arthrit is, have been carried out showing abnorma l 
uptak e to be lessened or normalised by effective treatment 
with non-steroidal anti-inflammatory drugs (NSAIDS) . Scans 
have also been useful for following the effects of 
treatment in rheumatoid arthritis . 
Whereas the maj ority of studies carried out in hospitals 
and in research establishments relate to stat i c imaging, in 
this study the imaging is early and active (dynamic) . 
Diphosphonate was used because the increased uptake was 
considered to result from its chemadsorption on to 
hydroxyapatite crystals in j uxta - articular cancellous bone 
which in most joint disease becomes abnormally vascular. 
Additionally, synovial vascularity also contributed to 
abnormal uptake . These two modalities are seen in this 
study as the amplitude (or asymptote) and the rate constant 
(or acretion rate) . In human knees , using Technetium 
M. D.P ., the rate constant levels of normality can be 
assessed and in the normal study the rate constant for 
normal knees is set at 1 .0. In an inflammed knee the rate 
constant will approach 2 .0 and in an ischaemic knee (which 
may be an osteoarthritic knee) will be below 1 . 0 , tending 
towards 0 . 5 . 
Photographs of each of these three models in the human are 
shown to exclude any doubt and to help differentiate 
between the three forms of arthritis (and thus rule out any 
confusion). Figure 7 . 1 shows normal knees, with effectively 
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Figure 7.1 shows on the upper l ine a norma l knee wi th 
normal amplitude (left) but slightly increased rate constant 
(Lambda) (right) , and on the lower line a normal k nee with 
normal amp l itude and rate constan t . 
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normal ampli t ude and normal r ate constant levels (Lambda) . 
Ea ch knee i s maximised in counts to its hottest spot. 
Figure 7.2 shows increased amplitude and increased rate 
constant which is t ypi ca l of the inflammatory model in the 
animal studies in this series of experiments . Figure 7 . 3 
sh ows increased amplitude and decreased rate constant 
equivalent to an ischaemic condition, and clearly cold , such 
as would be seen in the osteoarthritic (degenerative) model . 
In this experimental study evaluation of nove l compounds 
used as anti -inflammator y drugs in the arthritic 
comp laints, have been evaluated and questions asked in 
r espect of their true comparison with each other . 
The apparent determination of member firms of the 
Pharmaceutical Industry to compare their drugs in the most 
favoura b le light against other products from other firms is 
a ccepted as a na tura l event. Because of this, and in 
particular because of t hei r enthusiastic claims made on 
behalf of one of the drugs in this study, questions wh ich 
h ad to be asked were as muc h as to the objectivity of the 
design as we ll as the interpretation in animal and clinical 
trials. Certainly dosage rates of drugs appea r to b e chosen 
t o show the better points of the in - hous e drug against 
competitors ! 
Drugs have hitherto been evaluated b y a s eries of classical 
tests amongst which the adjuvant (Freunds ' ) complete 
arthritic r at hind paw volume study is just one. 
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Figure 7.2 Inflammatory model showing increased amplitude 
(left) and increased rate constant (right) in both upper and 
lower knees. 
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Figure 7.3 Comparison of upper inflammatory model with 
increased amplitude (left) and increased rate constant 
(right) with lower degenerative (osteoarthritic) model with 
increased amplitude (left) but decreased rate constant 
(right). 
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The true relevance of some of these tests should have been 
established far earlier as seen by the deaths of 70 elde rly 
patients due to side effects, the sUbject of recent 
unwelcome publicity . 
This study uses an absolutely objective test, that is, 
functi onal imaging, which is reproducible from each group 
of animal studies. The significance of this technique, 
which is truly pharmaco-dynamic , extends far beyond these 
speci fic effects , i.e . amplitude and rate constant results 
into the whole field or organ specific studies using a 
variety of isotopes . 
Weiner (1973) [29) and Kaihara (1969) [10) before him saw 
the value of these techniques in renal and hepatic studies 
using such isotopes . In pharmaco-dynamic studies, the 
technique i s used, for example , in the r enal transplant 
fi e l d. Because of its great flexibility it can identify 
parenchyrnal change long before biochemical parameters show 
any abnormality . By facilitating the objective comparison 
of drug effectiveness a far more specific watch can be kept 
on side effects , titrated against established anti-
inflammatory ac t ivity . 
The balance of effect against side effects, which today is 
based on subjective or clinical evaluation by the medical 
practitioner, can thus be made more scientific and indeed , 
considerably easier. 
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These particular advantages for the patient and for the 
physician are enhanced since the objectivity of the test 
permits quality control over some of the more extravagant 
claims made for any drug formulation in this field. 
Functional imaging thus permits the objective assessme nt of 
drug effects both desirable and detrimental . 
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8 . CONCLUSIONS 
1 . This test model is valid for the mathe mati ca l 
eva lua t i on of drug effect, with particular correlation 
to blood flow (Lambda) or rate constant values. The 
pattern is indistinguishable from the n ormal human 
c urves. 
2 . Amplitude or acretion rate is similarly ma t h e matically 
evaluable . 
3 . Because of the timing of the study, the problems o f 
bone to ECF l eakage of isotope is not r e l evant . Thi s 
compartme nt model can therefore be considered an 
exce llent research mode l. 
4. The claim of bone effect on osteoblastic/osteoclastic 
activity with particu l ar reference to Be noxaprof e n 
(Ill) have not been borne out. 
5. The test ha s a potential to become a significant 
screen for pharmaco-dynamic activity of nove l 
compou nds in the ant i-inflammatory ana l gesic field. 
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